Page 3 - எங்களுக்கு தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
MorphoSys AG Reports Second Quarter and First Half 2021 Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Invitation to MorphoSys Second Quarter and First Half 2021 Results Conference Call on July 29, 2021
ACCESSWIRE
22 Jul 2021, 06:31 GMT+10
PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT).
MorphoSys Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second quarter and first half financial results 2021 and provide a further outlook for 2021.
The conference call will start with a presentation by the Management Board followed by a Q&A session. Following Board Members will be on the call: